Efficacy and tolerability of moclobemide in bulimia nervosa: a placebo-controlled trial.

@article{Carruba2001EfficacyAT,
  title={Efficacy and tolerability of moclobemide in bulimia nervosa: a placebo-controlled trial.},
  author={Michele O. Carruba and Massimo Cuzzolaro and Laura Riva and Ottavio Bosello and Sascha Emilie Liberti and Rosy Castra and Riccardo Dalle Grave and Paolo Santonastaso and Vittorio Garosi and Enzo Nisoli},
  journal={International clinical psychopharmacology},
  year={2001},
  volume={16 1},
  pages={27-32}
}
A 6-week double-blind placebo-controlled trial was carried out to examine the efficacy and tolerability of moclobemide, a monoamine oxidase type A selective and reversible inhibitor, in the treatment of bulimia nervosa. Patients were admitted to the study even if they were unable to adhere to a tyramine-free diet. Fifty-two normal-weight women (age range 18-40 years) suffering from bulimia nervosa (DSM-IV criteria) completed the trial. Particular emphasis was placed on evaluating the incidence… CONTINUE READING